奎斯特诊断

最新新闻

• 评级变动
  A Quick Look at Today's Ratings for Quest Diagnostics(DGX.US), With a Forecast Between $232 to $260
  \u5e02\u573a\u8d44\u8baf · 2026/7/24
• Truist Financial Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $260
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• UBS Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $245
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• Truist Financial Maintains Quest Diagnostics(DGX.US) With Hold Rating, Maintains Target Price $260
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  BofA Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Raises Target Price to $245
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 公司公告
  GDEP Advance: Announcements of individual stocks: Orders for the NVIDIA DGX B200 GPU Appliance Server, equipped with NVIDIA B200, have begun.
  JPX · 2024/7/29
• 评级变动
  Mizuho Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Maintains Target Price $260
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• 评级变动
  Baird Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $236
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 公司公告
  Ryoyo Electro Corp: Lingyang Electronics begins to sell NVIDIA DGX Station (TM) A100, a new product of AI supercomputer.
  JPX · 2020/12/22
• 公司公告
  HPC Systems: HPC Systems delivers NVIDIA DGX H100 to Fujikura Ltd., contributing to further acceleration of Fujikura's diverse AI technology development
  JPX · 2023/7/5
• 评级变动
  J.P. Morgan Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $250
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• 评级变动
  Morgan Stanley Maintains Quest Diagnostics(DGX.US) With Buy Rating, Maintains Target Price $260
  \u5e02\u573a\u8d44\u8baf · 2026/8/19
• Barclays Maintains Quest Diagnostics(DGX.US) With Buy Rating, Raises Target Price to $260
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  William Blair Maintains Quest Diagnostics(DGX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  Barclays Maintains Quest Diagnostics(DGX.US) With Buy Rating, Maintains Target Price $230
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• 评级变动
  A Quick Look at Today's Ratings for Quest Diagnostics(DGX.US), With a Forecast Between $232 to $265
  \u5e02\u573a\u8d44\u8baf · 2026/7/25
• Barclays Maintains Quest Diagnostics(DGX.US) With Buy Rating, Maintains Target Price $250
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  Truist Financial Maintains Quest Diagnostics(DGX.US) With Hold Rating, Maintains Target Price $250
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• 评级变动
  Argus Research Maintains Quest Diagnostics(DGX.US) With Buy Rating, Raises Target Price to $260
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• Quest Diagnostics(DGX.US) Officer Sells US$5.51 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/1

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。